Doxorubicin Hydrochloride Tillomed: Withdrawal of the marketing authorisation application



Laboratorios Tillomed Spain S.L.U. withdrew its application for a marketing authorisation of Doxorubicin Hydrochloride Tillomed for the treatment of breast and ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma.

The company withdrew the application on 2 March 2020.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride pegylated liposomal concentrate for dispersion for infusion, 2 mg/ml) (PDF/132.78 KB)

    First published: 27/03/2020

  • Key facts

    Doxorubicin Hydrochloride Tillomed
    Product number
    International non-proprietary name (INN) or common name
    • doxorubicin
    Active substance
    • doxorubicin hydrochloride
    Date of withdrawal
    Company making the application
    Laboratorios Tillomed Spain S.L.U
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating
    3 ratings